China Shenwei Pharmaceutical Group Co., Ltd. (the “Company”) and its subsidiaries (hereinafter collectively referred to as the “Group”) are engaged in R&D, production and sales of modern traditional Chinese medicine injections, softgels, granular products and traditional Chinese medicine formula granules. The Group's products are mainly sold in the People's Republic of China (“China”) market. In the first six months of 2014, the Group's prescription and over-the-counter (“OTC”) turnover ratios were approximately 88.9% and 11.1 per cent, respectively. These products are mainly used in eight major fields of treatment, including cardiovascular medicine, respiratory medicine, digestive medicine, pediatric medicine, orthopedic medicine, corrective medicine, neurological medication, and gynecological medicine. The Group's main products are listed below: Qingkailing injection: A widely used antiviral drug to treat viral diseases, including respiratory infections, viral hepatitis, cerebral hemorrhage, and cerebral thrombosis Shuxenin injection: used to treat ischemic cardiovascular disease Shenmai injection: used to treat coronary heart disease, viral myocarditis, and cardiopulmonary diseases Wufu Xinnaoqing Softgels: For the prevention and treatment of coronary heart disease and cerebral arteriosclerosis Traditional Chinese medicine formula granules Agastache Zhengqi Softgels: For the prevention and treatment of heatstroke, abdominal pain, vomiting and diarrhea, and soil discomfort Pediatric lung cleansing and phlegm relief granules: for the treatment of respiratory infections in children Synovitis granules: for acute and chronic synovitis and treatment after joint surgery Qingkailing softgels: used to treat high fevers, viral colds, and respiratory infections